ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
You may also be interested in...
It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
Pfizer And Ionis’s Antisense Cholesterol Candidate Sparks Safety Worries
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.